

An original medical device for the fight against bacterial biofilms was registered in Russia

From **admin** - 12/14/2020

The **ALLOFARM** company received a registration certificate for the medical device "**Hydrogel coating for suppressing the development of bacterial biofilms ENTOMIX®**". RU number: RZN 2020/12582 dated 11/17/2020.

The main active ingredient is a complex of antimicrobial peptides FLIP7 (defensins, cecropins, dipterocins, proline-rich peptides) isolated from the immune system of insects (RF Patent No. peptides of insects ").

ENTOMIX® increases the effectiveness of medical procedures aimed at removing bacteria, both sensitive and resistant to antibiotics, from the wound cavity or the focus of inflammation. It can be used alone, or as an adjuvant to increase the effectiveness of antibiotic treatment, does not lead to the formation of bacterial resistance.

While the main information agenda for pharmacy and medicine remains the search for treatment options and prevention of viral infections, the World Health Organization once again publishes data on the increase in the number and prevalence of resistant strains. WHO has repeatedly called for the deliberate use of antibiotics, otherwise the problem of antibiotic resistance could turn into a global health disaster no less large and serious than the coronavirus infection **COVID-19**. Numerous scientific developments in the field of treatment of bacterial infections, filling the pages of scientific journals and covered in the media, remain within the walls of laboratories, without reaching the pharmacy counter.

Научный коллектив компании **АЛЛОФАРМ** ведёт свои исследования в области иммунной системы насекомых уже более 30 лет. За это время были открыты, запатентованы и нашли свое применение в практике не только антимикробные, но также противовирусные и противоопухолевые пептиды.

Применение гидрогелевого покрытия ЭНТОМИКС® на основе комплекса антимикробных пептидов FLIP7 позволит предупредить, замедлить, а, возможно, и остановить, формирование бактериальной устойчивости у бактерий.

В комплексной терапии ЭНТОМИКС® позволяет снизить эффективную концентрацию применяемого антибиотика или «реанимировать» уже неработающий антибиотик.

Не способность бактерий развить устойчивость к ЭНТОМИКС® гарантирует ему длительное будущее в медицине.

Clinical studies of the medical device were carried out at the N.V. I.I. Janelidze and Clinical Hospital No. 122 named after L.G. Sokolov in St. Petersburg on nosologies: burns, diabetic ulcer, pyoderma.

The company plans to continue researching ENTOMIX® in order to expand the indications and sees its promising applications in such areas as surgery, traumatology, phlebology, urology, otolaryngology.
